Clinical trial of personalized cancer vaccine demonstrates feasibility, safety, immune activation
The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic melanoma, was concluded with ...
18 hours ago
0
0









